Relevant bibliographies by topics / Non metastatic

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Non metastatic'

Author: Grafiati
Published: 4 June 2021
Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Non metastatic.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Non metastatic"

1

Trevizani, Maria Eduarda Salles, Fabio Albuquerque Marchi, Daniela Bizinelli, et al. "MicroRNA Profiles Distinguishing Metastatic from Non-Metastatic Salivary Mucoepidermoid Carcinoma." Journal of Clinical Medicine 14, no. 14 (2025): 4957. https://doi.org/10.3390/jcm14144957.

Full text
Abstract:
Background/Objectives: Mucoepidermoid carcinoma (MEC) is the most common malignant tumor of the salivary glands. Metastatic spread occurs in up to 80% of high-grade tumors; however, the mechanisms underlying this process are largely unknown. Large-scale microRNA (miRNA) expression profiling studies of human cancers have demonstrated that dysregulation of miRNA is frequently associated with many cancer types. This study aimed to investigate the miRNA profiles of metastatic and non-metastatic MECs. Methods: Using real-time RT-PCR (qPCR), we analyzed the expression of 377 miRNAs in four non-metas
APA, Harvard, Vancouver, ISO, and other styles
2

Trevizani, Maria Eduarda S., Katia K. Oliveira, Fabio A. Marchi, et al. "Abstract 3763: microRNAs associated with metastatic potential in salivary gland mucoepidermoid carcinoma." Cancer Research 83, no. 7_Supplement (2023): 3763. http://dx.doi.org/10.1158/1538-7445.am2023-3763.

Full text
Abstract:
Abstract Mucoepidermoid carcinoma (MEC) is the most common malignant tumor of the salivary glands. Metastatic spread occurs in up to 80% of high-grade tumors and it is a strong predictor of poor outcome, however, the mechanisms underlying this process are largely unknown. Large-scale microRNA expression profiling studies of human cancers have demonstrated that dysregulation of miRNA is frequently associated with many cancer types. The aim of this study was to investigate the microRNA profile in metastatic versus non-metastatic MECs. Using Real Time RT-PCR (qPCR) we have analyzed the expression
APA, Harvard, Vancouver, ISO, and other styles
3

Wu, Jie, Hong-Lei Cui, Hongzhe Shi, et al. "Clinicopathological characteristics and prognosis of metastatic non-clear cell renal cell carcinoma." Journal of Clinical Oncology 43, no. 5_suppl (2025): 504. https://doi.org/10.1200/jco.2025.43.5_suppl.504.

Full text
Abstract:
504 Background: Non-clear cell renal cell carcinoma (nccRCC) is a clinicopathological heterogeneous disease that comprises a complex mixture of different pathology subtypes, accounting for approximately 20% of all RCC cases. Due to its heterogeneity and rarity, standard treatment strategy for metastatic nccRCC remain poorly defined. Methods: We conducted retrospective analysis of 105 metastatic nccRCC patients at our center from June 2010 to April 2022. Demographic, clinicopathological, and systemic therapy data were collected. The data of 872 metastatic ccRCC patients were also collected for
APA, Harvard, Vancouver, ISO, and other styles
4

Wahyuni, Siska Dwiyantie, Sri Suryanti, Hasrayati Agustina, and Bethy Suryawathy Hernowo. "The Association of Clinicopathological Features with Metastatic Status in Infiltrative Urothelial Carcinoma of Bladder." Journal of Drug Delivery and Therapeutics 10, no. 6-s (2020): 99–102. http://dx.doi.org/10.22270/jddt.v10i6-s.4647.

Full text
Abstract:
Background: Infiltrative urothelial carcinoma of bladder is an aggressive variant of bladder carcinoma. Most of the patients in their first encounter with doctors are diagnosed with advanced stages and many has metastasized. Metastasis is a process of malignant tumor cells migrating from its primary tumor location to other organs or sites inside the body via blood circulation or lymphatic system. Metastasis process is responsible for 90% cancer deaths compared to the primary tumor itself, infiltrative urothelial carcinoma of bladder. To reduce mortality, knowledge of the clinicopathological ch
APA, Harvard, Vancouver, ISO, and other styles
5

Nestler, Tim, Priya Dalvi, Friederike Haidl, et al. "Transcriptome analysis reveals upregulation of immune response pathways at the invasive tumour front of metastatic seminoma germ cell tumours." British Journal of Cancer 126, no. 6 (2022): 937–47. http://dx.doi.org/10.1038/s41416-021-01621-5.

Full text
Abstract:
Abstract Background Testicular germ cell tumours (TGCTs) have a high metastasis rate. However, the mechanisms related to their invasion, progression and metastasis are unclear. Therefore, we investigated gene expression changes that might be linked to metastasis in seminomatous testicular germ cell tumour (STGCT) patients. Methods Defined areas [invasive tumour front (TF) and tumour centre (TC)] of non-metastatic (with surveillance and recurrence-free follow-up >2 years) and metastatic STGCTs were collected separately using laser capture microdissection. The expression of 760 genes related
APA, Harvard, Vancouver, ISO, and other styles
6

Alkhayat, Hana, and Chih-ho Hong. "Cutaneous Metastases from Non-Small Cell Lung Cancer." Journal of Cutaneous Medicine and Surgery 10, no. 6 (2006): 304–7. http://dx.doi.org/10.2310/7750.2006.00061.

Full text
Abstract:
Background: Cutaneous metastases are an uncommon phenomenon that occurs in a few patients with metastatic disease. Early recognition of a cutaneous metastasis is important as it may be the presenting sign of an underlying malignancy. These metastases usually indicate advanced disease and carry a poor prognosis. Objectives: We present two cases with cutaneous metastasis from primary non-small cell lung cancer. We seek to familiarize dermatologists with the unusual presentations of cutaneous metastases. Conclusion: In our two cases, the diagnosis of the metastatic cutaneous lesion ultimately led
APA, Harvard, Vancouver, ISO, and other styles
7

kia, Vahid, Yousef Mortazavi, Mahdi Paryan, Alireza Biglari, and Samira Mohammadi-Yeganeh. "Exosomal miRNAs from highly metastatic cells can induce metastasis in non-metastatic cells." Life Sciences 220 (March 2019): 162–68. http://dx.doi.org/10.1016/j.lfs.2019.01.057.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Suvilesh, Kanve Nagaraj, Yulia I. Nussbaum, Vijay Radhakrishnan, et al. "Abstract 267: Xenograft models of non-metastatic non-small cell lung cancer reveals micrometastasis-associated single cell composition." Cancer Research 82, no. 12_Supplement (2022): 267. http://dx.doi.org/10.1158/1538-7445.am2022-267.

Full text
Abstract:
Abstract Background: Circulating tumor cells (CTCs) represent micrometastatic disease and may offer unique insights into future recurrences in lethal malignancies, including non-small cell lung cancer (NSCLC). Due to CTC rarity and limited stability, no CTC-derived xenograft (CDX) models have ever been generated from non-metastatic NSCLC patients directly. Alternative strategies are needed to molecularly characterize CTCs in this potentially curable patient group. Methods: Surgically resected NSCLC primary tumor tissues were implanted in immunodeficient mice to establish ten patient-derived xe
APA, Harvard, Vancouver, ISO, and other styles
9

Trevizani, Maria E., Katia K. Oliveira, Fabio A. Marchi, et al. "Abstract 2999: Evaluation of microRNA expression in metastatic and non-metastatic salivary gland mucoepidermoid carcinoma." Cancer Research 84, no. 6_Supplement (2024): 2999. http://dx.doi.org/10.1158/1538-7445.am2024-2999.

Full text
Abstract:
Abstract Salivary gland tumors are a heterogeneous group of lesions, being mucoepidermoid carcinoma (MEC) the malignant neoplasm with the highest incidence, occurring mainly in the parotid gland. Characterization of its histological grade (high, intermediate, and low) is important for determining patient prognosis. Metastasis is more common high-grade tumors and can occur at regional lymph nodes or distant sites. Although the mechanisms underlying the metastatic process are largely unknown, large-scale microRNA expression profiling studies of human cancers have demonstrated that dysregulation
APA, Harvard, Vancouver, ISO, and other styles
10

Mulhauser, Kyler, Dario A. Marotta, Adam Gerstenecker, et al. "Capacity to consent to research participation in adults with metastatic cancer: comparisons of brain metastasis, non-CNS metastasis, and healthy controls." Neuro-Oncology Practice 7, no. 4 (2020): 439–45. http://dx.doi.org/10.1093/nop/npaa008.

Full text
Abstract:
Abstract Background To evaluate the ability of individuals with metastatic cancer to provide informed consent to research participation, we used a structured vignette-based interview to measure 4 consenting standards across 3 participant groups. Methods Participants included 61 individuals diagnosed with brain metastasis, 41 individuals diagnosed with non-CNS metastasis, and 17 cognitively intact healthy controls. All groups were evaluated using the Capacity to Consent to Research Instrument (CCRI), a performance-based measure of research consent capacity. The ability to provide informed conse
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Non metastatic"

1

Solberg, Arne. "Outcome Assessments in Non- Metastatic Prostate Cancer." Doctoral thesis, Norges teknisk-naturvitenskapelige universitet, Institutt for kreftforskning og molekylær medisin, 2011. http://urn.kb.se/resolve?urn=urn:nbn:no:ntnu:diva-13881.

Full text
Abstract:
Metoder for å måle utfall av behandling hos pasienter med prostatakreft uten spredning. Prostatakreft uten påvist spredning kan behandles med operasjon, strålebehandling med eller uten hormonbehandling, eller hormonbehandling alene. Svært mange menn med nylig påvist prostatakreft vil imidlertid kunne leve i mange år uten plager av sykdommen også uten behandling, og en stor andel dør til slutt av helt andre årsaker enn prostatkreft. Man mangler imidlertid helt sikre metoder for å velge ut pasienter som ikke trenger behandling, men i noen tilfeller hvor sykdommen er i tidlig fase er et regelmess
APA, Harvard, Vancouver, ISO, and other styles
2

Chen, Dongsheng. "Transcriptional regulation of the p9Ka gene in metastatic and non-metastatic rat mammary epithelial cells." Thesis, University of Liverpool, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.266488.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hulgaard, Egil F. "Identification and characterisation of differentially displayed transcripts in metastatic versus non-metastatic cells of the CSML cell line system." Thesis, Open University, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.264475.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Borniger, Jeremy C. "Effects of Non-Metastatic Mammary Tumors and Cytotoxic Chemotherapy on Murine Sleep." The Ohio State University, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=osu1492420724807522.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nordman, Ina IC Clinical School St Vincent's Hospital Faculty of Medicine UNSW. "Surrogate endpoints of survival in metastatic carcinoma." Publisher:University of New South Wales. Clinical School - St Vincent's Hospital, 2008. http://handle.unsw.edu.au/1959.4/42791.

Full text
Abstract:
In most randomised controlled trials (RCTs), a large number of patients need to be followed over many years, for the clinical benefit of the drug to be accurately quantified (1). Using an early proxy, or a surrogate endpoint, in place of the direct endpoint of overall survival (OS) could theoretically shorten the duration of RCTs and minimise the exposure of patients to ineffective or toxic treatments (2, 3). This thesis examined the relationship between surrogate endpoints and OS in metastatic colorectal cancer (CRC), advanced non-small cell lung cancer (NSCLC) and metastatic breast cancer (M
APA, Harvard, Vancouver, ISO, and other styles
6

Fortin, Bernard 1970. "Waiting time for radiation therapy in non-metastatic, surgically-treated breast cancer patients in Quebec." Thesis, McGill University, 2003. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=80266.

Full text
Abstract:
The purpose of this study was to determine among surgically treated non-metastatic breast cancer patients in the province of Quebec the distribution of the time between surgery and post-operative radiation therapy (RT) as well as secular trends and other factors influencing waiting time. Using administrative records, I identified between 1992 and 1998 29,105 episodes of breast cancer and 17,704 of these contained an indication of receiving RT Hierarchical linear regression models were used to identify predictors of waiting time.<br>The number of cases of breast cancer increased by 5.5%
APA, Harvard, Vancouver, ISO, and other styles
7

Aljohani, Hashim M. "Targeting Tyrosine Kinase Drug Resistance Mechanisms and Metastatic Pathways in Brain Tumors." University of Cincinnati / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1595846160285645.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, Kai. "Developing Novel Carriers to Deliver Targeted Immunotoxins for the Treatment of Primary and Metastatic Non-Small Cell Lung Cancer." Thesis, Griffith University, 2017. http://hdl.handle.net/10072/365662.

Full text
Abstract:
Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer which is a leading cause of cancer death. Most patients (>80%) present with advanced NSCLC when curative surgery is no longer an option. Other conventional therapies, such as chemotherapy, radiotherapy and existing molecular targeted therapy have neither significantly extended the life span of most patients, nor improved their quality of life. This is not only because of the large tumor load in the advanced stage of NSCLC but its metastasis. This project devises a novel approach to shield the “magic bullet” and help it locate a
APA, Harvard, Vancouver, ISO, and other styles
9

Blat, Irene Catherine. "Functional miRNA regulation of metastatic genes promotes tumor cell dissemination in non-small cell and small cell lung carcinomas." Thesis, Massachusetts Institute of Technology, 2013. http://hdl.handle.net/1721.1/80982.

Full text
Abstract:
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Biology, 2013.<br>Cataloged from PDF version of thesis. Vita.<br>Includes bibliographical references.<br>Tumor progression, from initiation to advanced metastatic disease, requires the orchestration of a diverse group of cell-intrinsic and extrinsic factors. This multifactorial disease is promoted by an accumulation of genetic and epigenetic changes that confer selective advantage to cells and enable unrestrained proliferation, survival, motility, and self-renewal. While much emphasis over the last 35 years has been dedicated to
APA, Harvard, Vancouver, ISO, and other styles
10

Iwakiri, Shotaro. "Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I non-small cell lung cancer." Kyoto University, 2009. http://hdl.handle.net/2433/124265.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Non metastatic"

1

Jordan, Nerissa. Non-metastatic neurological manifestations of malignancy. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0238.

Full text
Abstract:
Neurological complications of systemic malignancy are frequent. They may reflect direct local effects of the tumour; CNS infection; side effects of chemotherapy or radiotherapy; nutritional or metabolic derangements; or a paraneoplastic syndrome. The paraneoplastic neurological syndromes are a group of disorders associated with a malignancy outside the nervous system. The pathophysiology is immune-mediated, with the tumour’s expression of neuronal proteins invoking antibody formation, which in turn results in neurological symptoms. This chapter will mainly focus on these syndromes.
APA, Harvard, Vancouver, ISO, and other styles
2

National Comprehensive Cancer Network® (NCCN®). NCCN Guidelines for Patients® Non-Small Cell Lung Cancer Metastatic. National Comprehensive Cancer Network® (NCCN®), 2022.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

NCCN Guidelines for Patients® Metastatic Non-Small Cell Lung Cancer. National Comprehensive Cancer Network® (NCCN®), 2023.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gray, Nathan A., and Thomas W. LeBlanc. Early Palliative Care for Patients with Metastatic Non-Small Cell Lung Cancer (DRAFT). Edited by Nathan A. Gray and Thomas W. LeBlanc. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190658618.003.0001.

Full text
Abstract:
This chapter provides an overview and commentary on the 2010 study by Temel and colleagues regarding early palliative care for patients with non-small cell lung cancer. It describes the trial design and findings while also providing a concise critique of the study and a brief review of relevant subsequent studies. The chapter describes the basics of the study, including funding, year study began, year study was published, study location, who was studied, who was excluded, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. The chap
APA, Harvard, Vancouver, ISO, and other styles
5

Hirsh, Vera, and Barbara Melosky, eds. The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine. Frontiers Media SA, 2015. http://dx.doi.org/10.3389/978-2-88919-543-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hirsh, Vera, and Barbara Melosky, eds. Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine. Frontiers Media SA, 2018. http://dx.doi.org/10.3389/978-2-88945-397-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Goepel, John. Pathology of testicular tumours. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0091.

Full text
Abstract:
Tumours of the testis are uncommon and are usually germ cell tumours. They present most often as a scrotal mass in a young man, and are the most frequent malignant tumour in this age group. The incidence has risen over recent decades and is higher in Western Europe. A history of testicular maldescent is a significant risk factor. About 50% are pure seminoma; the remainder non-seminomas may have a single but more usually a mixed histology. Non-seminomas are all called teratoma in the British system. Metastasis readily occurs to paraaortic lymph nodes or the lungs, and some patients present with
APA, Harvard, Vancouver, ISO, and other styles
8

Healey, John H., and David McKeown. Orthopaedic surgery in the palliation of cancer. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656097.003.0125.

Full text
Abstract:
Metastatic spread of cancer to bone is frequent and causes pain, disability, and functional limitation. New understanding of the homing method of cancer cells to bone and the mechanism of cancer production of pain raise possible new treatment strategies. Non-surgical treatments such as chemotherapy and hormone therapy are effective in early disease. Bisphosphonates and inhibition of osteoprotegerin prevent progression of bone lesions and avoid pain, radiation, and surgery. Radiotherapy arrests disease and relieves pain in many cases. Surgery is needed when the bone is weak or fractured. It eff
APA, Harvard, Vancouver, ISO, and other styles
9

Zehnder, Pascal, and George N. Thalmann. Muscle-invasive bladder cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0078.

Full text
Abstract:
In the United Kingdom, &gt;4,000 people die of bladder cancer every year. This reflects around one-third of affected patients and occurs in those with primary metastatic disease, with invasion at presentation, and in persons whose tumour progresses to invasion from non-invasive disease. The outcome from invasive cancers has not dramatically altered over the last 30 years, due to a lack of screening programmes, a lack of advances in treatment, and the fact that many patients present with tumours at an advanced stage. Around 50% of patients with invasive disease die from bladder cancer despite r
APA, Harvard, Vancouver, ISO, and other styles
10

Agarwal, Rajiv, and Andrew S. Epstein. Expectations about Effects of Chemotherapy in Patients with Advanced Cancer (DRAFT). Edited by Nathan A. Gray and Thomas W. LeBlanc. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190658618.003.0033.

Full text
Abstract:
This chapter reviews the Weeks et al. secondary analysis of data from the Cancer Care Outcomes Research and Surveillance (CanCORS) prospective cohort, evaluating the expectations of patients who receive chemotherapy for incurable metastatic lung or colorectal cancer. Patients’ understanding of the effectiveness of chemotherapy for providing cure, life extension, and symptom relief were measured. The researchers also investigated the clinical, sociodemographic, and health system factors that were associated with inaccurate expectations on the curative potential of chemotherapy. The study demons
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Non metastatic"

1

Fong, Zhi Ven, George A. Poultsides, and Motaz Qadan. "Patient Selection and Guidelines for Resection and Liver-Directed Therapies: Non-colorectal, Non-neuroendocrine Liver Metastases." In Primary and Metastatic Liver Tumors. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-91977-5_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Challapalli, Amarnath, and Emily Renninson. "Treatment of Locally Advanced and Metastatic Skin Carcinomas." In Non-melanoma Skin Cancer. CRC Press, 2023. http://dx.doi.org/10.1201/9781003226017-23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Freiha, F. S. "Carcinoma of the Prostate — Non-metastatic Disease." In Combination Therapy in Urological Malignancy. Springer London, 1989. http://dx.doi.org/10.1007/978-1-4471-1655-4_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lin, Tzu-En. "Monitoring Tyrosinase Expression in Non-metastatic and Metastatic Melanoma Tissues by SECM." In Soft Probes for Bio-electrochemical Imaging. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-05758-9_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Subbiah, Ishwaria, Cathy Eng, and Emil Lou. "Managing Non-Hepatic Metastatic Sites: Lung and CNS." In Comprehensive Rectal Cancer Care. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-98902-0_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bozkurt, Yunus Erol, and Turgay Turan. "Enzalutamide Therapy for Metastatic Prostate Cancer." In Current Management of Metastatic Prostate Cancer. Nobel Tip Kitabevleri, 2024. http://dx.doi.org/10.69860/nobel.9786053359142.7.

Full text
Abstract:
Enzalutamide (ENZ), a potent androgen receptor pathway inhibitor, gained FDA approval in 2012 for metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel chemotherapy. It exhibits high affinity to the androgen receptor (AR), disrupting AR signaling crucial for prostate cancer growth. Notably, ENZ’s mechanism inhibits AR nuclear translocation and exerts apoptotic effects, distinct from older antiandrogens like bicalutamide. Clinical trials demonstrate ENZ’s efficacy across various stages of prostate cancer, from metastatic hormone-sensitive disease to non-metastatic CRPC, prolong
APA, Harvard, Vancouver, ISO, and other styles
7

Ong, J., R. T. D. Oliver, J. Shamash, et al. "Metastatic Seminoma: Should Treatment Be Different from Non-seminoma?" In Germ Cell Tumours V. Springer London, 2002. http://dx.doi.org/10.1007/978-1-4471-3281-3_54.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ritch, Chad R., and Michael S. Cookson. "Clinical Scenario: Large Volume, Non-metastatic T2 Bladder Tumor." In Management of Bladder Cancer. Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1881-2_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sittadjody, Sivanandane, Thilakavathy Thangasamy, Bita NickKolgh, and K. C. Balaji. "Non-androgen Signaling Pathways in Castration-Resistant Prostate Cancer." In Managing Metastatic Prostate Cancer In Your Urological Oncology Practice. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-31341-2_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Brod, J. L., R. Kühn, W. Schafhauser, and K. M. Schrott. "Radiochemotherapy in Locally Invasive Non-Metastatic Carcinoma of the Bladder." In Bladder Disease, Part A. Springer US, 2003. http://dx.doi.org/10.1007/978-1-4419-8889-8_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Non metastatic"

1

Sayyad, Megan, Madhavi Puchalapalli, Chris Canal, Theresa Swift-Scanlan, Andrew Ottens, and Jennifer E. Koblinski. "Abstract 1988: Metastatic v non-metastatic cancer exosomes in brain metastasis." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1988.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sayyad, Megan, Madhavi Puchalapalli, Chris Canal, Theresa Swift-Scanlan, Andrew Ottens, and Jennifer E. Koblinski. "Abstract 1988: Metastatic v non-metastatic cancer exosomes in brain metastasis." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1988.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kim, H. S., Y. H. Cho, A. B. Frazier, Z. G. Chen, D. M. Shin, and A. Han. "Whole Cell Impedance Analysis of Metastatic and Non-Metastatic Cancer Cells." In 2009 IEEE 22nd International Conference on Micro Electro Mechanical Systems (MEMS). IEEE, 2009. http://dx.doi.org/10.1109/memsys.2009.4805403.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Coutinho-Camillo, Cláudia M., Renato D. Puga, Cibele P. Nagano, et al. "Abstract 4005: microRNA profiles in metastatic versus non-metastatic salivary mucoepidermoid carcinoma." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rasul, Raisa B., Mason G. Harper, and Narasimhan Rajaram. "Intravital imaging of tumor bioenergetics in metastatic and non-metastatic breast cancer." In Diseases in the Breast and Reproductive System IV, edited by Melissa C. Skala and Paul J. Campagnola. SPIE, 2018. http://dx.doi.org/10.1117/12.2289621.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sayyad, Megan, Madhavi Puchalapalli, Bin Hu, and Jennifer Koblinski. "Abstract 47: Brain metastatic versus non-metastatic breast cancer exosomes influence astrocyte response." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-47.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

K, Sooraj, Sandeep Goswami, Sunil Kumar, Swati Shukla, Neelam Pushker, and Jasbir Kaur. "Abstract 3603: Differential gene expression of metastatic and non-metastatic human uveal melanoma." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-3603.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ellsworth, RE, AL Valente, LA Field, et al. "Abstract P4-06-09: Genetic Signature Discriminating Metastatic from Non-Metastatic Small Tumors." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p4-06-09.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Andolino, Chaylen, Josie Asher, Alyssa S. Zembroski, Kimberly Buhman, and Dorothy Teegarden. "Abstract 3744: Differences in lipid metabolism between non-metastatic and metastatic breast cancer cells." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-3744.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kwiecień, Iwona, Elżbieta Rutkowska, Joanna Bednarek, et al. "T cell maturation profile in metastatic vs. non-metastatic lymph nodes in NSCLC patients." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa681.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Non metastatic"

1

Tinker, Anna V., Neesha C. Dhani, Prafull Ghatage, et al. Immune Checkpoint Inhibitors in Pretreated Metastatic Endometrial Cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.1.0038.

Full text
Abstract:
Review question / Objective: Efficacy and safety of immune checkpoint inhibitors alone or in combination with tyrosine kinase inhibitors in patients with pretreated advanced, persistent, or recurrent metastatic endometrial cancer. Condition being studied: Advanced, persistent, or recurrent metastatic endometrial cancer. Study designs to be included: Non-randomized studies of monotherapy in populations selected for relevant biomarkers such as MMR, microsatellite stability, and PD-L1 expression status and randomized trials of ICI combinations in unselected patients.
APA, Harvard, Vancouver, ISO, and other styles
2

Zhang, Huan, Laiyan Zhou, and Jianxin Xue. Neoadjuvant Immunotherapy for non-metastatic rectal Cancer: A systematic review and meta‑analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.7.0110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

DING, YACONG, WANG YANSONG, TANG MO, ZHAI JIAWEI, LI RUI, and YANG YUFEI. Performance of Prediction Models of Non-Metastatic Colorectal Cancer : A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.11.0130.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ponvilawan, Ben, Dhruv Bansal, Nagla Abdel Karim, and Janakiraman Subramanian. Long-term survival outcomes of first-line immune checkpoint inhibitor in PD-L1 negative metastatic non-small cell lung cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.8.0120.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chen, Cheng-Che, and Hao-En Lin. Survival Benefits and Bleeding Risk of Anti-VEGF Agents for Renal Cell Carcinoma (RCC): A Updated Systematic Review and Meta-Analysis of Phase 2 and 3 Randomized Clinical Trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.3.0007.

Full text
Abstract:
Review question / Objective: To investigate the survival benefits (PFS, DFS, OS) and bleeding risk of the anti-VEGF agents compared with placebo or interferon alpha (IFNa) in patients with RCC. Condition being studied: Part 1. The hazard ratio (HR) of the progression-free survival (PFS) and overall survival (OS) of anti-VEGF agents vs. non/placebo for patients with unresectable, advanced, metastatic, renal cell carcinoma (RCC). Part 2. The HR of the disease-free survival (PFS) and OS of anti-VEGF agents vs. non/placebo for patients with post-nephrectomy RCC (adjuvant use). Part 3. The HR of th
APA, Harvard, Vancouver, ISO, and other styles
6

Dang, Jun, Linzheng Dai, Bo Jin, Tingting Liu, and Jun Chen. The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.4.0025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hertelendi, Marianna, Oulaya Belguenani, Azzeddine Cherfi, Ilya Folitar, Gabor Kollar, and Berna Degirmenci Polack. Protocol for a systematic literature review of efficacy and safety of [177Lu]Lu-DOTA-TATE in adults with inoperable or metastatic somatostatin receptor-positive pheochromocytomas/paragangliomas, bronchial and unknown origin neuroendocrine tumors, and medullary thyroid carcinoma. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.3.0030.

Full text
Abstract:
Review question / Objective: The aim of this systematic review is to identify and summarize the use of [177Lu]Lu-DOTA-TATE as a treatment for neuroendocrine tumors (NETs) of non-gastroenteropancreatic (GEP) origin to understand evolving clinical practice. Condition being studied: Adults (as defined by the authors) with any of the following inoperable or metastatic SSTR-positive NETs: PPGL, thymic NET, bronchial NET, NET of unknown primary origin, or MTC. Efficacy and safety outcomes were analyzed. Eligibility criteria: Search included studies published up to May 13, 2021. No geographic, langua
APA, Harvard, Vancouver, ISO, and other styles
8

Zhao, Hao, Chunhao Liu, Yanlong Li, and Xiaoyi Li. Prognostic factors for survival in differentiated thyroid cancer with pulmonary metastases: a protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.2.0026.

Full text
Abstract:
Pulmonary metastasis (PM) is the most common form of distance metastasis in differentiated thyroid cancer (DTC), which has a poor prognosis. However, the prognostic risk factors are not yet well identified and analyzed. This systematic review and meta-analysis aims to fill this blank though identifying and discussing survival prognostic risk factors systematically for DTC patients with PM. Pulmonary metastasis (PM) is the most common form of distance metastasis in differentiated thyroid cancer (DTC), which has a poor prognosis. However, the prognostic risk factors are not yet well identified a
APA, Harvard, Vancouver, ISO, and other styles
9

Sriuranpong, Virote. The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable nonmetastasis NSCLC as a prognostic marker of disease. Chulalongkorn University, 2010. https://doi.org/10.58837/chula.res.2010.16.

Full text
Abstract:
Introduction; Despite adequate surgical management of stage I non-small cell lung cancer, many patients still have relapsed of disease which leads to mortality. Micrometastasis of tumor is the postulate mechanism which might not be detected by standard H&amp;E method. The author conducted the study of epithelial methylation marker, SHP-1 Promoter 2 (SHP1P2) methylation as a potential molecular marker to detect high risk relapsed of disease in stage I resectable non-small cell lung cancer (NSCLC). Method; To explore the potential role of SHP1P2 methylation to detect micrometastasis, Lymph node
APA, Harvard, Vancouver, ISO, and other styles
10

Watson, Mark A. Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada606182.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Non metastatic' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography